Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2011, Article ID 415719, 5 pages
http://dx.doi.org/10.1155/2011/415719
Review Article

Cinacalcet Treatment of Primary Hyperparathyroidism

Division of Nephrology and Hypertension, Medical Department, Klinikum Coburg III, D-96450 Coburg, Germany

Received 6 December 2010; Accepted 4 January 2011

Academic Editor: Faustino R. Pérez-López

Copyright © 2011 H. M. Rothe et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. J. Silverberg, H. G. Bone 3rd, T. B. Marriott et al., “Short-term inhibition of parathyroid hormone secretion by a calcium-receptor agonist in patients with primary hyperparathyroidism,” New England Journal of Medicine, vol. 337, no. 21, pp. 1506–1510, 1997. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Yamauchi, T. Sugimoto, T. Yamaguchi et al., “Association of polymorphic alleles of the calcium-sensing receptor gene with the clinical severity of primary hyperparathyroidism,” Clinical Endocrinology, vol. 55, no. 3, pp. 373–379, 2001. View at Publisher · View at Google Scholar · View at Scopus
  3. T. Kawata, Y. Imanishi, K. Kobayashi et al., “Relationship between parathyroid calcium-sensing receptor expression and potency of the calcimimetic, cinacalcet, in suppressing parathyroid hormone secretion in an in vivo murine model of primary hyperparathyroidism,” European Journal of Endocrinology, vol. 153, no. 4, pp. 587–594, 2005. View at Publisher · View at Google Scholar
  4. M. L. Dillon and L. A. Frazee, “Cinacalcet for the treatment of primary hyperparathyroidism,” American Journal of Therapeutics. In press. View at Publisher · View at Google Scholar · View at Scopus
  5. H. Padmanabhan, “Cinacalcet in the treatment of intractable hypercalcemia following two neck exploration surgeries for primary hyperparathyroidism,” Southern Medical Journal, vol. 103, no. 3, pp. 272–275, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. D. G. Sheldon, F. T. Lee, N. J. Neil et al., “Surgical treatment of hyperparathyroidism improves health-related quality of life,” Archives of Surgery, vol. 137, no. 9, pp. 1022–1028, 2002. View at Google Scholar · View at Scopus
  7. A. Sitges-Serra, L. Garcia, R. Prieto, M. J. Pena, X. Nogues, and J. J. Sancho, “Effect of parathyroidectomy for primary hyperparathyroidism on bone mineral density in postmenopausal women,” British Journal of Surgery, vol. 97, no. 7, pp. 1013–1019, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. Y. Auroy, D. Benhamou, F. Pequignot, M. Bovet, E. Jougla, and A. Lienhart, “Mortality related to anaesthesia in France: analysis of deaths related to airway complications,” Anaesthesia, vol. 64, no. 4, pp. 366–370, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Glenshaw and F. D. Madzimbamuto, “Anaesthesia associated mortality in a district hospital in Zimbabwe: 1994 to 2001,” Central African Journal of Medicine, vol. 51, no. 3-4, pp. 39–44, 2005. View at Google Scholar · View at Scopus
  10. S. Sajid-Crockett, F. R. Singer, and J. M. Hershman, “Cinacalcet for the treatment of primary hyperparathyroidism,” Metabolism, vol. 57, no. 4, pp. 517–521, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Peacock, J. P. Bilezikian, P. S. Klassen, M. D. Guo, S. A. Turner, and D. Shoback, “Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism,” Journal of Clinical Endocrinology and Metabolism, vol. 90, no. 1, pp. 135–141, 2005. View at Publisher · View at Google Scholar
  12. D. M. Shoback, J. P. Bilezikian, S. A. Turner, L. C. McCary, M. D. Guo, and M. Peacock, “The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism,” Journal of Clinical Endocrinology and Metabolism, vol. 88, no. 12, pp. 5644–5649, 2003. View at Publisher · View at Google Scholar · View at Scopus
  13. P. Iglesias, G. Ais, A. González et al., “Acute and one-year effects of cinacalcet in patients with persistent primary hyperparathyroidism after unsuccessful parathyroidectomy,” American Journal of the Medical Sciences, vol. 335, no. 2, pp. 111–114, 2008. View at Publisher · View at Google Scholar
  14. C. Marcocci, P. Chanson, D. Shoback et al., “Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism,” Journal of Clinical Endocrinology and Metabolism, vol. 94, no. 8, pp. 2766–2772, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. B. Akinci, A. Comlekci, and E. Tankurt, “Hypercalcemia of primary hyperparathyroidism was treated by cinacalcet in a patient with liver cirrhosis,” Experimental and Clinical Endocrinology and Diabetes, vol. 117, no. 3, pp. 142–145, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. T. Berndt and R. Kumar, “Phosphatonins and the regulation of phosphate homeostasis,” Annual Review of Physiology, vol. 69, pp. 341–359, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Peacock, M. A. Bolognese, M. Borofsky et al., “Cinacalcet treatment of primary hyperparathyroidism: biochemical and bone densitometric outcomes in a five-year study,” Journal of Clinical Endocrinology and Metabolism, vol. 94, no. 12, pp. 4860–4867, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. G. Vezzoli, A. Terranegra, T. Arcidiacono et al., “R990G polymorphism of calcium-sensing receptor does produce a gain-of-function and predispose to primary hypercalciuria,” Kidney International, vol. 71, no. 11, pp. 1155–1162, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. H. M. Rothe, W. B. Shapiro, W. Y. Sun, and S. Y. Chou, “Calcium-sensing receptor gene polymorphism Arg990Gly and its possible effect on response to cinacalcet HCl,” Pharmacogenetics and Genomics, vol. 15, no. 1, pp. 29–34, 2005. View at Google Scholar · View at Scopus
  20. H. Rothe, W. B. Shapiro, W. Y. Sun, and A. Matalon, “Calcium-sensing receptor gene polymorphism Arg990Gly influences the response to calcimimetic agents in end-stage kidney disease patients with secondary hyperparathyroidism,” Personalized Medicine, vol. 5, no. 2, pp. 109–116, 2008. View at Google Scholar
  21. K. Kalantar-Zadeh, J. E. Miller, C. P. Kovesdy et al., “Impact of race on hyperparathyroidism, mineral disarrays, administered vitamin D mimetic, and survival in hemodialysis patients,” Journal of Bone and Mineral Research, vol. 25, no. 12, pp. 2448–2458, 2010. View at Publisher · View at Google Scholar
  22. I. H. de Boer, I. Gorodetskaya, B. Young, C. Y. Hsu, and G. M. Chertow, “The severity of secondary hyperparathyroidism in chronic renal insufficiency is GFR-dependent, race-dependent, and associated with cardiovascular disease,” Journal of the American Society of Nephrology, vol. 13, no. 11, pp. 2762–2769, 2002. View at Publisher · View at Google Scholar · View at Scopus
  23. G. Vezzoli, A. Terranegra, T. Arcidiacono et al., “Calcium kidney stones are associated with a haplotype of the calcium-sensing receptor gene regulatory region,” Nephrology Dialysis Transplantation, vol. 25, no. 7, pp. 2245–2252, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. A. L. Serra, A. A. Schwarz, F. H. Wick, H. P. Marti, and R. P. Wuthrich, “Successful treatment of hypercalcemia with cinacalcet in renal transplant recipients with persistent hyperparathyroidism,” Nephrology Dialysis Transplantation, vol. 20, no. 7, pp. 1315–1319, 2005. View at Publisher · View at Google Scholar · View at Scopus
  25. M. E. Cho, Z. Duan, C. E. Chamberlain, J. C. Reynolds, M. S. Ring, and R. B. Mannon, “Cinacalcet improves bone density in post-kidney transplant hyperparathyroidism,” Transplantation Proceedings, vol. 42, no. 9, pp. 3554–3558, 2010. View at Publisher · View at Google Scholar
  26. L. K. Potter, L. D. Greller, C. R. Cho et al., “Response to continuous and pulsatile PTH dosing: a mathematical model for parathyroid hormone receptor kinetics,” Bone, vol. 37, no. 2, pp. 159–169, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. N. Franceschini, M. S. Joy, and A. Kshirsagar, “Cinacalcet HCl: a calcimimetic agent for the management of primary and secondary hyperparathyroidism,” Expert Opinion on Investigational Drugs, vol. 12, no. 8, pp. 1413–1421, 2003. View at Publisher · View at Google Scholar · View at Scopus